Gerald Cox will step down as the CMO of Editas at later this year, the company has announced. No reason was given for his departure and no announcement has been made concerning Cox's future plans. The news comes as the company, which is focused on treating a form of severe blindness caused by a rare genetic disorder, finally announced plans to begin clinical trials the end of year. Following lengthy delays, Editas' lead candidate, EDIT-101, which aims to treat the disease LCA10, is expected to be filed in October. Shares in the company were down nearly 2.5% following the news.
Gerald Cox will step down as the CMO of Editas at the end of year, the company has announced. No reason was given for his departure and no announcement has been made concerning Cox's future plans. The news comes as the company, which is focused on treating a form of severe blindness caused by a rare genetic disorder, finally announced plans to begin clinical trials later this year. Following lengthy delays, Editas' lead candidate, EDIT-101, which aims to treat the disease LCA10, is expected to be filed in October. Shares in the company were down nearly 2.5% following the news.